Ignite Creation Date:
2024-10-26 @ 3:41 PM
Last Modification Date:
2024-10-26 @ 3:41 PM
Study NCT ID:
NCT06615700
Status:
COMPLETED
Last Update Posted:
None
First Post:
2024-09-24
Brief Title:
Phase 1 to Study Safety Tolerability Pharmacokinetics and Pharmacodynamics of NA-931 in Obese Participants and Patients With Type 2 Diabetes Mellitus
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Randomized Double-Blind Placebo-Controlled Phase 1 Study to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of NA-931 in OverweightObese Participants and in Patients With Type 2 Diabetes Mellitus
Status:
COMPLETED
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
T2DM
Brief Summary:
A randomized double-blind placebo-controlled dose escalation first in human study designed to assess the safety and tolerability pharmacokinetics and pharmacodynamics of NA-931 when administered as single and multiple-ascending doses in overweightobese participants and as multiple doses in patients with T2DM
Detailed Description:
A randomized double-blind placebo-controlled dose escalation first in human study designed to assess the safety and tolerability pharmacokinetics and pharmacodynamics of NA-931 when administered as single and multiple-ascending doses in overweightobese participants and as multiple doses in patients with Type 2 Diabetes Mellitus
NA-931 is a Quadruple Receptor Agonist for Insulin Like Growth Factor 1 IGF-1 Glucagon-like Peptide-1 GLP-1 Gastric Inhibitory Polypeptide GIP and Glucagon
NA-931 is a Quadruple Receptor Agonist for Insulin Like Growth Factor 1 IGF-1 Glucagon-like Peptide-1 GLP-1 Gastric Inhibitory Polypeptide GIP and Glucagon
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None